# Open Label Extension In Cancer Patients

> **NCT00830180** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 41 (actual)

## Conditions studied

- Neoplasms
- Bone Metastases

## Interventions

- **BIOLOGICAL:** Anti-NGF AB

## Key facts

- **NCT ID:** NCT00830180
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-29
- **Primary completion:** 2013-02-14
- **Final completion:** 2013-02-14
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2021-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00830180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00830180, "Open Label Extension In Cancer Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00830180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*